|
News For AMRN From The Last 14 Days Check below for free stories on AMRN the last two weeks. |
|
|
| May 22, 2013 |
| 11:56 EDT |  | AMRN | Options with decreasing implied volatility: WCRX NTI PXP AMRN BBY
|
|
| 06:07 EDT |  | AMRN | Amarin announces patent allowance related to combination of Vascepa, Statin
Amarin announced that the United States Patent and Trademark Office has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/417,899 titled "Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same." This application includes claims intended to protect the Vascepa indication approved by the FDA based on Amarin's MARINE clinical trial results specifically those results seen in patients on statin therapy. The claims in this allowed application cover a method to reduce triglycerides in subjects having a triglyceride level of 500mg/dl to 1500mg/dl who are also receiving statin therapy using an amount of Vascepa effective to reduce triglycerides without substantially increasing low density lipoprotein cholesterol. |
|
| May 21, 2013 |
| 11:41 EDT | | AMRN | Options with decreasing implied volatility: SGMO WCRX NTI TSLA AMRN
|
|
| May 17, 2013 |
| 14:12 EDT | | AMRN | Amarin shares slip after FDA updates Orange Book
 Subscribe for More Information |
|
| May 15, 2013 |
| 11:04 EDT |  | AMRN | Amarin management to meet with Lazard Capital
Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. |
|
| May 13, 2013 |
| 12:52 EDT | | AMRN | Amarin strength attributed to MassHealth drug list addition
Subscribe for More Information |
|
| May 10, 2013 |
| 09:23 EDT |  | AMRN | Amarin continues to make progress with payors, says Leerink
Leerink reiterates an Outperform rating on shares of Amarin following the company's Q1 results. The firm believes Amarin continues to make good progress with payors and that Vascepa script trends are tracking well. |
|
| May 9, 2013 |
| 16:18 EDT |  | AMRN | Amarin reports Q1 EPS (41c), consensus (39c)
Reports Q1 revenue $2.34M, consensus $5.2M. Amarin said its direct sales force, consisting of approximately 275 sales professionals, made sales calls to clinicians for two months in Q1. Amarin reports that, since launch, access to clinicians has been good, and that it has yet to hear any significant negative reaction to the efficacy or safety profile of Vascepa. Amarin said it continues to make significant progress in its effort to expand patent protection for Vascepa and now has 22 patents issued or allowed in the United States with over 30 additional U.S. patent applications being prosecuted. |
|
| 13:15 EDT | | AMRN | Amarin, Omthera drop following fatty acids study in journal
Subscribe for More Information |
|
|
|
|
|
